GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AbbVie ABBV · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

S&P 500

Compare

293.30

+0.68%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

38 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 10Strong buy
  • 21Buy
  • 7Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Last close 293.30Average target 285.54

Low
235.00
Average
285.54
Median
296.00
High
300.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$67.58bn$73.54bn$79.11bn$83.50bn$85.28bn
Revenue, highest$67.93bn$74.91bn$81.87bn$84.84bn$86.65bn
Revenue, lowest$67.44bn$71.90bn$75.38bn$81.60bn$83.33bn
Earnings per share13.9116.2917.8819.7920.96
Earnings per share, highest14.2117.2720.8320.2021.40
Earnings per share, lowest13.7715.4215.4319.2120.34
Analysts1918221411

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast3.823.682.652.711.812.942.432.16
Reported3.823.652.652.711.862.972.462.16
Difference-0.1%-0.7%+0.2%+0.2%+2.7%+0.9%+1.1%+0.0%

Rating changes

Latest broker notes

  • Wells FargoOverweight
  • Wolfe ResearchPeer Perform → Outperform
  • BNP ParibasNeutral
  • Evercore ISI GroupOutperform
  • GuggenheimBuy
  • Cantor FitzgeraldOverweight
  • Canaccord GenuityBuy
  • BarclaysOverweight
  • Canaccord GenuityBuy
  • CitigroupNeutral
  • UBSNeutral
  • BMO CapitalOutperform

Recent targets

Latest 12 months

  • HSBC315.00
  • Piper Sandler303.00
  • Wells Fargo300.00
  • Wolfe Research300.00
  • Guggenheim288.00
  • Morgan Stanley296.00
  • Canaccord Genuity290.00
  • Barclays300.00

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

3 / 10

Revenue growth 10.3% a year over 10 years. Return on equity -130.9%.

Model fair value

735.40

From earnings 735.40, from revenue 217.71.

Piotroski score

6 / 9

A nine-point test of financial strength, for 31 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.